Susquehanna International Group, LLP Bellus Health Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $182,268 - $282,714	-28,215 Reduced 47.18%	31,584 $292,000
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $742,182 - $1.07 Million	-133,486 Reduced 69.06%	59,799 $411,000
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $684,615 - $1.08 Million	130,155 Added 206.17%	193,285 $1.56 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $170,451 - $419,183	63,130 New	63,130 $388,000
Q2 2021 Aug 11, 2021	SELL	$3.11 - $4.61 $41,462 - $61,460	-13,332 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $40,395 - $61,060	13,332 New	13,332 $51,000
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $239,587 - $1.35 Million	-111,957 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $597,535 - $750,283	-67,290 Reduced 37.54%	111,957 $1.15 Million
Q1 2020 May 15, 2020	BUY	$5.77 - $10.85 $934,578 - $1.76 Million	161,972 Added 937.61%	179,247 $1.79 Million
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $99,504 - $131,290	17,275 New	17,275 $131,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.